[ad_1]
NEW YORK, March 28, 2022 /PRNewswire/ — The fibrin sealants market is expected to grow by USD 1.06 bn between 2021 and 2026 and register a CAGR of 8.62%, according to Technavio’s estimates. With a focus on identifying dominant industry influencers, Technavio’s reports present a detailed study by the way of synthesis and summation of data from multiple sources. This report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.
Utilize Technavio’s market insights to obtain growth opportunities. Read Free Sample Report
Fibrin Sealants Market 2022-2026: Vendor Analysis and Scope
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. To leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments while maintaining their positions in the slow-growing segments.
To help businesses improve their market position, the fibrin sealants market provides a detailed analysis of around 25 vendors operating in the market. Some of these vendors include Asahi Kasei Corp., Baxter International Inc., Becton Dickinson and Co., Cryolife Inc., CSL Ltd., Grifols SA, Johnson and Johnson, Pharming Group NV, Reliance Industries Ltd., Shanghai RAAS Blood Products Co. Ltd., Stryker Corp., Takeda Pharmaceutical Co. Ltd., Tissuemed Ltd., and Vivostat AS. The key offerings of some of these vendors are listed below:
- Asahi Kasei Corp. – The company offers fibrin sealants that are used in therapies such as dialysis, therapeutic apheresis, blood transfusion, bio process..
- Baxter International Inc. – The company offers fibrin sealants that include tisseel, which helps surgeons address bleeding in sites inaccessible to sutures and cautery.
- Becton Dickinson and Co. – The company offers fibrin sealants that help control bleeding during surgery, such as dialysis, therapeutic apheresis, blood transfusion, bio process.
The report…
[ad_2]
